Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2016 2
2017 1
2020 1
2021 2
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study.
Diletti R, Karanasos A, Muramatsu T, Nakatani S, Van Mieghem NM, Onuma Y, Nauta ST, Ishibashi Y, Lenzen MJ, Ligthart J, Schultz C, Regar E, de Jaegere PP, Serruys PW, Zijlstra F, van Geuns RJ. Diletti R, et al. Eur Heart J. 2014 Mar;35(12):777-86. doi: 10.1093/eurheartj/eht546. Epub 2014 Jan 6. Eur Heart J. 2014. PMID: 24394380 Free article.
AIMS: We evaluated the feasibility and the acute performance of the everolimus-eluting bioresorbable vascular scaffolds (BVS) for the treatment of patients presenting with ST-segment elevation myocard
AIMS: We evaluated the feasibility and the acute performance of the everolimus-eluting bioresorbable vascular
Serial Baseline, 12-, 24-, and 60-Month Optical Coherence Tomography Evaluation of ST Segment Elevation Myocardial Infarction Patients Treated with Absorb Bioresorbable Vascular Scaffold.
Koltowski L, Tomaniak M, Ochijewicz D, Zieliński K, Proniewska K, Malinowski KP, Zaleska M, Maksym J, Roleder T, Partyka L, Kochman W, Filipiak KJ, Opolski G, Kochman J. Koltowski L, et al. Am J Cardiol. 2021 Sep 15;155:23-31. doi: 10.1016/j.amjcard.2021.05.038. Epub 2021 Jul 25. Am J Cardiol. 2021. PMID: 34315572
Data on long-term neointimal healing and neoatherosclerosis progression after primary percutaneous coronary intervention (PCI) with implantation of everolimus-eluting bioresorbable vascular scaffold (BVS) (ABSORB BVS 1.0, Abbott Vascular) …
Data on long-term neointimal healing and neoatherosclerosis progression after primary percutaneous coronary intervention (PCI) with implanta …
Outcomes after complete dissolution of everolimus-eluting bioresorbable scaffolds implanted during routine practice.
Wiebe J, Hoppmann P, Cassese S, Rheude T, Colleran R, Kuna C, Rai H, Valeskini M, Ibrahim T, Joner M, Schunkert H, Laugwitz KL, Kastrati A, Byrne RA. Wiebe J, et al. Rev Esp Cardiol (Engl Ed). 2021 Jul;74(7):584-590. doi: 10.1016/j.rec.2020.07.005. Epub 2020 Aug 18. Rev Esp Cardiol (Engl Ed). 2021. PMID: 32819850 English, Spanish.
INTRODUCTION AND OBJECTIVES: Long-term outcomes of unselected patients treated with bioresorbable vascular scaffold (BVS) implantation are lacking, especially for the period after complete dissolution of the BVS. ...The patients were followed-up …
INTRODUCTION AND OBJECTIVES: Long-term outcomes of unselected patients treated with bioresorbable vascular scaffold
Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI).
Kajiya T, Liang M, Sharma RK, Lee CH, Chan MY, Tay E, Chan KH, Tan HC, Low AF. Kajiya T, et al. EuroIntervention. 2013 Aug 22;9(4):501-4. doi: 10.4244/EIJV9I4A80. EuroIntervention. 2013. PMID: 23687101 Free article.
AIMS: Recent studies have demonstrated favourable clinical outcomes for the everolimus-eluting bioresorbable vascular scaffold (BVS) ABSORB in patients with stable coronary artery disease. There are currently no data on its use in pati
AIMS: Recent studies have demonstrated favourable clinical outcomes for the everolimus-eluting bioresorbable vascula
Expanded clinical use of everolimus eluting bioresorbable vascular scaffolds for treatment of coronary artery disease.
Diletti R, Ishibashi Y, Felix C, Onuma Y, Nakatani S, van Mieghem NM, Regar E, Valgimigli M, de Jaegere PP, van Ditzhuijzen N, Fam JM, Ligthart JMR, Lenzen MJ, Serruys PW, Zijlstra F, Jan van Geuns R. Diletti R, et al. Catheter Cardiovasc Interv. 2017 Jul;90(1):58-69. doi: 10.1002/ccd.26832. Epub 2016 Nov 29. Catheter Cardiovasc Interv. 2017. PMID: 27896897
BACKGROUND: Limited data are currently available on the performance of everolimus eluting bioresorbable vascular scaffold (BVS) for treatment of complex coronary lesions representative of daily practice. METHODS: This is a prospective, mo …
BACKGROUND: Limited data are currently available on the performance of everolimus eluting bioresorbable vascular
Everolimus-eluting bioresorbable scaffold versus everolimus-eluting metallic stent in primary percutaneous coronary intervention of ST-segment elevation myocardial infarction: a randomized controlled trial.
Eriksen E, Neghabat O, Saeed S, Herstad J, Nordrehaug JE, Tuseth V, Holm NR, Holck EN, Sejr-Hansen M, Maule CF, Barkholt TØ, Andreasen LN, Christiansen EH, Bleie Ø. Eriksen E, et al. Coron Artery Dis. 2023 Jan 1;34(1):1-10. doi: 10.1097/MCA.0000000000001202. Epub 2022 Nov 22. Coron Artery Dis. 2023. PMID: 36484214 Clinical Trial.
BACKGROUND: Primary percutaneous coronary intervention with implantation of a metallic drug-eluting stent (DES) is the standard treatment for patients presenting with ST-elevation myocardial infarction (STEMI). ...Patients w …
BACKGROUND: Primary percutaneous coronary intervention with implantation of a metallic drug-eluting stent (DES) is the standard tr
Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold: The BVS Expand Registry.
Felix CM, Fam JM, Diletti R, Ishibashi Y, Karanasos A, Everaert BR, van Mieghem NM, Daemen J, de Jaegere PP, Zijlstra F, Regar ES, Onuma Y, van Geuns RJ. Felix CM, et al. JACC Cardiovasc Interv. 2016 Aug 22;9(16):1652-63. doi: 10.1016/j.jcin.2016.04.035. Epub 2016 Jul 27. JACC Cardiovasc Interv. 2016. PMID: 27476094 Free article.
BACKGROUND: Multiple studies have proven feasibility and safety of the Absorb bioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa Clara, California). ...METHODS: This is an investigator-initiated, prospective, single-center, single-arm study …
BACKGROUND: Multiple studies have proven feasibility and safety of the Absorb bioresorbable vascular scaffold (BVS) (Ab …